Diabetes Mellitus: a Prothrombotic State Implications for Outcomes After Coronary Revascularization

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2009 May 14

PMID 19436654

Citations 6

Authors

Clarissa Cola

Salvatore Brugaletta

Victoria Martin Yuste

Bieito Campos

Dominick J Angiolillo

Manel Sabate

Affiliations

Soon will be listed here.

Abstract

Coronary stent thrombosis is a serious problem in the drug-eluting stent era. Despite aggressive antiplatelet therapy during and after percutaneous coronary intervention (PCI), the incidence of sub-acute stent thrombosis remains approximately 0.5%-2%, which may represent a catastrophic clinical situation. Both procedural factors and discontinuation of antiplatelet therapy are normally associated with this event. We report on simultaneous stent thromboses of two drug-eluting stents implanted in two different vessels, which resulted in a life-threatening clinical condition. Possible contributing factors that led to synergistic thrombotic effects are discussed.

Citing Articles

Diabetes Mellitus and Clinical Outcomes in Carotid Artery Revascularization Using Second-Generation, MicroNet-Covered Stents: Analysis from the PARADIGM Study.

Mazurek A, Borratynska A, Gancarczyk U, Czyz L, Sikorska M, Tekieli L J Diabetes Res. 2022; 2022:8691842.

PMID: 36200003 PMC: 9529505. DOI: 10.1155/2022/8691842.

Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.

Otamas A, Grant P, Ajjan R Diab Vasc Dis Res. 2020; 17(3):1479164120920582.

PMID: 32506946 PMC: 7607413. DOI: 10.1177/1479164120920582.

Comparison of clinical outcomes after drug-eluting stent implantation in diabetic versus nondiabetic patients in China: A retrospective study.

Jiang Y, Han W, Gao C, Feng J, Chen Z, Zhang J Medicine (Baltimore). 2017; 96(17):e6647.

PMID: 28445265 PMC: 5413230. DOI: 10.1097/MD.0000000000006647.

Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

Balasubramaniam K, Viswanathan G, Marshall S, Zaman A Cardiol Res Pract. 2012; 2012:909154.

PMID: 22347666 PMC: 3278919. DOI: 10.1155/2012/909154.

Clinical importance of aspirin and clopidogrel resistance.

Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B World J Cardiol. 2010; 2(7):171-86.

PMID: 21160749 PMC: 2998916. DOI: 10.4330/wjc.v2.i7.171.

References

Vinik A, Erbas T, Park T, Nolan R, Pittenger G . Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001; 24(8):1476-85. DOI: 10.2337/diacare.24.8.1476. View

Michelson A . Platelet function testing in cardiovascular diseases. Circulation. 2004; 110(19):e489-93. DOI: 10.1161/01.CIR.0000147228.29325.F9. View

Watala C . May the alterations in lipid fluidity-mediated platelet hypersensitivity contribute to accelerated aging of platelets in diabetes mellitus?. Med Hypotheses. 1991; 36(2):142-5. DOI: 10.1016/0306-9877(91)90257-y. View

Kapur A, Malik I, Bagger J, ANDERSON J, Kooner J, Thomas M . The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J. 2005; 149(1):13-9. DOI: 10.1016/j.ahj.2004.07.001. View

Finn A, Kolodgie F, Harnek J, Guerrero L, Acampado E, Tefera K . Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005; 112(2):270-8. DOI: 10.1161/CIRCULATIONAHA.104.508937. View

Colwell J . Aspirin therapy in diabetes. Diabetes Care. 2002; 26 Suppl 1:S87-8. DOI: 10.2337/diacare.26.2007.s87. View

Gurbel P, Bliden K, Hayes K, Yoho J, Herzog W, Tantry U . The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005; 45(9):1392-6. DOI: 10.1016/j.jacc.2005.01.030. View

Stahli B, Camici G, Steffel J, Akhmedov A, Shojaati K, Graber M . Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res. 2006; 99(2):149-55. DOI: 10.1161/01.RES.0000233379.92010.fd. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

10.

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

11.

Pamukcu B . A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis. 2006; 23(3):213-22. DOI: 10.1007/s11239-006-9043-2. View

12.

Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N . Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost. 2006; 4(12):2566-8. DOI: 10.1111/j.1538-7836.2006.02183.x. View

13.

Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W . One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol. 2007; 50(17):1627-34. DOI: 10.1016/j.jacc.2007.07.035. View

14.

Steffel J, Latini R, Akhmedov A, Zimmermann D, Zimmerling P, Luscher T . Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005; 112(13):2002-11. DOI: 10.1161/CIRCULATIONAHA.105.569129. View

15.

Angiolillo D, Costa M, Shoemaker S, Desai B, Bernardo E, Suzuki Y . Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol. 2008; 101(4):440-5. DOI: 10.1016/j.amjcard.2007.09.087. View

16.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Stankovic G . Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17):2126-30. DOI: 10.1001/jama.293.17.2126. View

17.

Lieuw-a-Fa M, van Hinsbergh V, Teerlink T, Barto R, Twisk J, Stehouwer C . Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant. 2004; 19(3):631-6. DOI: 10.1093/ndt/gfg619. View

18.

Vorchheimer D, Badimon J, Fuster V . Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999; 281(15):1407-14. DOI: 10.1001/jama.281.15.1407. View

19.

Zimmermann N, Wenk A, Kim U, Kienzle P, Weber A, Gams E . Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003; 108(5):542-7. DOI: 10.1161/01.CIR.0000081770.51929.5A. View

20.

Mauri L, Hsieh W, Massaro J, Ho K, DAgostino R, Cutlip D . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356(10):1020-9. DOI: 10.1056/NEJMoa067731. View